DDInter927 DDInter212
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952.
Bisacodyl {u} (Compound) resembles {v} (Compound) Carbinoxamine
Bisacodyl {u} (Compound) resembles {v} (Compound) Dexbrompheniramine
Bisacodyl {u} (Compound) binds {v} (Gene) GPR55
Bisacodyl {u} (Compound) upregulates {v} (Gene) KTN1
Bisacodyl {u} (Compound) is included by {v} (Pharmacologic Class) Stimulation Large Intestine Fluid/Electrolyte Secretion
Bisacodyl {u} (Compound) downregulates {v} (Gene) MTMR4
Bisacodyl {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Bisacodyl {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Bisacodyl (Compound) resembles Dexbrompheniramine (Compound)
Bisacodyl (Compound) binds GPR55 (Gene)
Bisacodyl (Compound) upregulates KTN1 (Gene)
Bisacodyl (Compound) is included by Stimulation Large Intestine Fluid/Electrolyte Secretion (Pharmacologic Class)
Bisacodyl (Compound) downregulates MTMR4 (Gene)
Bisacodyl (Compound) causes Nervous system disorder (Side Effect)
Bisacodyl may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant